Daily Anesthesiology Research Analysis
Three impactful anesthesiology-related papers stand out today: a preclinical human-neuron chimeric mouse study uncovers a DVL-1–mediated mechanism for sevoflurane’s neurodevelopmental impact and suggests neuromodulatory rescue, a translational eLife study shows that peripherally restricted μ-opioid receptor antagonism can reverse fentanyl-induced respiratory depression without aversive effects, and a double-blind RCT demonstrates intraoperative S-ketamine reduces rebound pain after total knee ar
Summary
Three impactful anesthesiology-related papers stand out today: a preclinical human-neuron chimeric mouse study uncovers a DVL-1–mediated mechanism for sevoflurane’s neurodevelopmental impact and suggests neuromodulatory rescue, a translational eLife study shows that peripherally restricted μ-opioid receptor antagonism can reverse fentanyl-induced respiratory depression without aversive effects, and a double-blind RCT demonstrates intraoperative S-ketamine reduces rebound pain after total knee arthroplasty. These works span mechanistic insight, overdose therapeutics, and perioperative analgesia optimization.
Research Themes
- Anesthetic neurodevelopmental safety and mechanisms
- Opioid-induced respiratory depression: peripheral reversal strategies
- Perioperative analgesia optimization and rebound pain mitigation
Selected Articles
1. Human neuron chimeric mice reveal impairment of DVL-1-mediated neuronal migration by sevoflurane and potential treatment by rTMS.
Using human cerebral organoids and human neuron chimeric mice, sevoflurane was shown to specifically impair human neuronal migration in vivo while also inhibiting differentiation and synaptogenesis in vitro. Chemogenetic activation rescued migration defects and social dysfunction, and the mechanism involves inhibition of DVL-1–mediated signaling, with potential neuromodulatory (e.g., rTMS) therapeutic implications.
Impact: Addresses a high-stakes anesthesiology question—neurodevelopmental effects of sevoflurane—using human-relevant models and identifies a mechanistic pathway (DVL-1) with a potential rescue strategy.
Clinical Implications: Although preclinical, the findings support minimizing prolonged/repeated sevoflurane exposure in early development and motivate monitoring developmental outcomes. They also open avenues for neuromodulatory adjuncts to mitigate potential effects.
Key Findings
- Sevoflurane inhibited human neuronal migration in vivo in human neuron chimeric mice, while in vitro it suppressed differentiation and synaptogenesis.
- Chemogenetic activation of human neurons rescued migration defects and social dysfunction in sevoflurane-pretreated chimeric mice.
- Mechanistic data implicate inhibition of DVL-1–mediated signaling; title suggests rTMS as a potential therapeutic approach.
Methodological Strengths
- Multiple complementary human-relevant systems (organoids and human neuron chimeric mice).
- Mechanistic rescue via chemogenetic activation provides causal support.
Limitations
- Preclinical models; dose/exposure paradigms may not fully reflect clinical anesthetic practices.
- Long-term functional outcomes and translatability to human infants remain uncertain.
Future Directions: Define clinically relevant exposure thresholds, validate neuromodulatory rescue (e.g., rTMS) in additional models, and integrate longitudinal neurodevelopmental assessments in at-risk clinical cohorts.
Whether early exposure to general anesthetics hurts human brain development is still under discussion. Animal studies have documented multiple neurotoxicities of repeated/prolonged exposure to sevoflurane (Sev, a commonly used pediatric anesthetic) at the neonatal stage. Its effects on human neural development remain elusive. Here, by investigating neural progenitor cells derived from two human embryonic stem cell lines, human cerebral organoids and human neuronal chimeric mice, we found that, although Sev inhibits neuronal differentiation and synaptogenesis of human neural progenitor cells in vitro, it only inhibits human neuronal migration in vivo. Chemogenetic activation of human neurons rescued the defects of cell migration and social dysfunction of Sev-pretreated human neuronal chimeric mice. Mechanistically, Sev inhibits DVL-1/Ca
2. Peripheral opioid receptor antagonism alleviates fentanyl-induced cardiorespiratory depression and is devoid of aversive behavior.
A peripherally restricted μ-opioid receptor antagonist (naloxone methiodide) both prevented and reversed fentanyl-induced respiratory depression in vivo to a degree comparable to naloxone, but without aversive behaviors. Electrophysiologic and circuit-level data implicate peripheral MORs and ascending inputs to the nucleus of the solitary tract, suggesting a therapeutic path to reverse OIRD while minimizing CNS-mediated withdrawal and aversion.
Impact: Provides a compelling mechanistic and therapeutic advance for OIRD—a central problem in perioperative care and the opioid crisis—by targeting peripheral MORs to avoid CNS side effects.
Clinical Implications: If translated clinically, peripherally restricted MOR antagonists could reverse fentanyl overdoses without precipitating severe CNS-mediated withdrawal or aversion, potentially improving EMS and perioperative rescue strategies.
Key Findings
- Naloxone methiodide (peripherally restricted) prevented and reversed fentanyl-induced respiratory depression comparably to naloxone.
- Peripheral MOR antagonism did not elicit aversive behaviors seen with naloxone.
- nTS neuronal activity changes after fentanyl were attenuated by peripheral antagonism, implicating ascending peripheral inputs in OIRD pathophysiology.
Methodological Strengths
- Comprehensive in vivo and circuit-level analyses linking behavior, respiratory physiology, and neural activity.
- Use of peripherally restricted antagonist to dissect peripheral vs central MOR contributions.
Limitations
- Preclinical animal data; human pharmacokinetics, dosing, and safety profiles require evaluation.
- Scope limited to fentanyl; generalizability to other opioids needs confirmation.
Future Directions: First-in-human studies of peripherally restricted MOR antagonists for OIRD reversal, dose-ranging, and comparative effectiveness versus naloxone in EMS and perioperative settings.
Millions of Americans suffering from Opioid Use Disorders face a high risk of fatal overdose due to opioid-induced respiratory depression (OIRD). Fentanyl, a powerful synthetic opioid, is a major contributor to the rising rates of overdose deaths. Reversing fentanyl overdoses has proved challenging due to its high potency and the rapid onset of OIRD. We assessed the contributions of central and peripheral mu opioid receptors (MORs) in mediating fentanyl-induced physiological responses. The peripherally restricted MOR antagonist naloxone methiodide (NLXM) both prevented and reversed OIRD to a degree comparable to that of naloxone (NLX), indicating substantial involvement of peripheral MORs to OIRD. Interestingly, NLXM-mediated OIRD reversal did not produce aversive behaviors observed after NLX. We show that neurons in the nucleus of the solitary tract (nTS), the first central synapse of peripheral afferents, exhibit a biphasic activity profile following fentanyl exposure. NLXM pretreatment attenuates this activity, suggesting that these responses are mediated by peripheral MORs. Together, these findings establish a critical role for peripheral MORs, including ascending inputs to the nTS, as sites of dysfunction during OIRD. Furthermore, selective peripheral MOR antagonism could be a promising therapeutic strategy for managing OIRD by sparing CNS-driven acute opioid-associated withdrawal and aversion observed after NLX.
3. S-Ketamine Reduces the Risk of Rebound Pain in Patients Following Total Knee Arthroplasty: A Randomized Controlled Trial.
In a double-blind RCT of 356 TKA patients, intraoperative S-ketamine infusion reduced 12-hour rebound pain incidence (21.3% vs 34.8%; adjusted RR 0.62), delayed RP onset, lowered early pain, reduced opioid use, and improved recovery quality and satisfaction without new safety signals.
Impact: Provides level I evidence for a simple intraoperative intervention to mitigate clinically problematic rebound pain after TKA, with immediate applicability to anesthetic practice.
Clinical Implications: Consider intraoperative S-ketamine infusion as part of multimodal analgesia for TKA to reduce rebound pain and improve early recovery, with monitoring for psychotomimetic effects per institutional protocols.
Key Findings
- S-ketamine reduced 12-hour postoperative rebound pain incidence (21.3% vs 34.8%; adjusted RR 0.62).
- Delayed onset of rebound pain and prolonged time to first rescue analgesia.
- Improved early pain scores, decreased opioid consumption, and higher patient satisfaction within 3 days.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with adequate sample size.
- Predefined clinically relevant primary and secondary outcomes with in-person follow-up.
Limitations
- Short follow-up (3 days) limits assessment of later outcomes and functional recovery.
- Single dosing regimen and surgical context (TKA) may limit generalizability to other procedures.
Future Directions: Evaluate optimal dosing/timing, extend follow-up for functional outcomes and chronic pain, and test in other surgeries and high-risk populations.
PURPOSE: Investigating the effectiveness of S-ketamine in reducing rebound pain (RP) following total knee arthroplasty. PATIENTS AND METHODS: This study was a randomized, double-blind, placebo-controlled trial involving 356 adult patients undergoing total knee arthroplasty. Patient enrollment occurred between April and October 2023, with in-person follow-up assessments conducted from admission to 3 days post-surgery. Participants were randomly assigned to the S-ketamine group (n = 178) and the placebo group (n = 178). In the S-ketamine group, participants received a continuous intraoperative infusion of S-ketamine at a dose of 0.30 mg/(kg·h) from the completion of spinal anesthesia until the beginning of joint cavity closure, whereas the placebo group received a continuous infusion of 0.9% saline at the same volume and duration. The primary outcome was the incidence of RP within 12 hours post-surgery. Secondary outcomes included the incidence of RP within 24 hours, time to RP onset, time to first rescue analgesia, pain scores, opioid consumption, clinical outcomes, and harms. RESULTS: RP was observed in 21.3% of patients in the S-ketamine group compared with 34.8% in the placebo group within 12 hours post-surgery (adjusted RR, 0.62; 95% CI, 0.44 to 0.88; CONCLUSIONS: S-ketamine effectively reduces the risk of rebound pain and delays its onset in total knee arthroplasty. Additionally, S-ketamine can reduce early pain levels, enhance recovery quality, and improve patient satisfaction.